Log in

NASDAQ:BIBProShares Ultra Nasdaq Biotechnology Stock Price, Forecast & News

+0.67 (+0.88 %)
(As of 07/9/2020 04:00 PM ET)
Today's Range
Now: $77.00
50-Day Range
MA: $70.21
52-Week Range
Now: $77.00
Volume200,400 shs
Average Volume229,605 shs
Market Capitalization$238.70 million
P/E RatioN/A
Dividend Yield0.00%
ProShares Ultra Nasdaq Biotechnology (the Fund) seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day's returns compounded over the period, which will very likely differ from the inverse of the return of the Dow Jones United States Basic Materials Index (the Index) for that period. The Fund does not seek to achieve its stated investment objective over a period of time greater than one day. The Fund invests in derivatives that have similar daily performance characteristics as the inverse of the daily return of the Index. The Fund invests in financial instruments whose value is derived from the value of an underlying asset, interest rate or index. ProShare Advisors LLC is the investment advisor of the Fund.
Read More

Geographic Exposure of BIB

Currency Exposure of BIB

Sector Exposure of BIB

Industry Exposure of BIB

Basic Details

Issuer ProShares
Fund NameProShares Ultra Nasdaq Biotechnology
Tax ClassificationRegulated Investment Company
Inception Date4/6/2010
Fund ManagerMichael Neches, Tarak Dave

Fund Focus

Asset ClassEquity
BenchmarkNasdaq Biotech Index
FocusHealth Care
Development LevelDeveloped Markets
RegionNorth America

Fund Statistics

Assets Under Management$193.76 million
Average Daily Volume$162,193.00

ETF Expenses

Management Fee0.75%
Other Expenses0.29%
Total Expenses1.04%
Fee Waiver-0.09%
Net Expenses0.95%

Administrator, Advisor and Custodian

AdministratorJ.P. Morgan Investor Services Co.
AdvisorProShare Advisors LLC
CustodianJPMorgan Chase Bank, N.A.
DistributorSEI Investments Distribution Co.
Transfer AgentJPMorgan Chase Bank, N.A.
Lead Market MakerVirtu Financial

Receive BIB News and Ratings via Email

Sign-up to receive the latest news and ratings for BIB and its competitors with MarketBeat's FREE daily newsletter.

ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Frequently Asked Questions

How has ProShares Ultra Nasdaq Biotechnology's stock been impacted by COVID-19 (Coronavirus)?

ProShares Ultra Nasdaq Biotechnology's stock was trading at $47.23 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, BIB stock has increased by 63.0% and is now trading at $77.00. View which stocks have been most impacted by Coronavirus.

Has ProShares Ultra Nasdaq Biotechnology been receiving favorable news coverage?

Media stories about BIB stock have trended negative on Friday, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. ProShares Ultra Nasdaq Biotechnology earned a news impact score of -2.3 on InfoTrie's scale. They also assigned news articles about the exchange traded fund a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news about ProShares Ultra Nasdaq Biotechnology.

What other stocks do shareholders of ProShares Ultra Nasdaq Biotechnology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ProShares Ultra Nasdaq Biotechnology investors own include Walt Disney (DIS), Gilead Sciences (GILD), Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), Alibaba Group (BABA), Starbucks (SBUX), salesforce.com (CRM), Cisco Systems (CSCO) and Netflix (NFLX).

What is ProShares Ultra Nasdaq Biotechnology's stock symbol?

ProShares Ultra Nasdaq Biotechnology trades on the NASDAQ under the ticker symbol "BIB."

How do I buy shares of ProShares Ultra Nasdaq Biotechnology?

Shares of BIB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is ProShares Ultra Nasdaq Biotechnology's stock price today?

One share of BIB stock can currently be purchased for approximately $77.00.

How big of a company is ProShares Ultra Nasdaq Biotechnology?

ProShares Ultra Nasdaq Biotechnology has a market capitalization of $238.70 million.

What is ProShares Ultra Nasdaq Biotechnology's official website?

The official website for ProShares Ultra Nasdaq Biotechnology is www.proshares.com.

How can I contact ProShares Ultra Nasdaq Biotechnology?

ProShares Ultra Nasdaq Biotechnology's mailing address is SUITE 1000, 7501 WISCONSIN AVENUE, BETHESDA, MD 20814, United States. The exchange traded fund can be reached via phone at +1-240-4976400.

This page was last updated on 7/10/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.